Shares of Medical Transcription Billing, Corp. (NASDAQ:MTBC) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokers have set a one year consensus target price of $3.88 for the company, according to Zacks. Zacks has also given Medical Transcription Billing an industry rank of 107 out of 265 based on the ratings given to related companies.

Several brokerages have commented on MTBC. Zacks Investment Research raised Medical Transcription Billing from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Wednesday, August 16th. ValuEngine lowered Medical Transcription Billing from a “hold” rating to a “sell” rating in a research report on Monday. Finally, Chardan Capital raised their price objective on Medical Transcription Billing from $2.25 to $2.75 and gave the company a “buy” rating in a research report on Tuesday, November 14th.

Medical Transcription Billing (MTBC) opened at $2.61 on Friday. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 0.01. Medical Transcription Billing has a fifty-two week low of $0.29 and a fifty-two week high of $5.44.

In related news, President Stephen Andrew Snyder sold 50,000 shares of Medical Transcription Billing stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $3.18, for a total value of $159,000.00. Following the completion of the sale, the president now directly owns 106,000 shares in the company, valued at approximately $337,080. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Mahmud Ul Haq acquired 30,000 shares of Medical Transcription Billing stock in a transaction that occurred on Friday, December 1st. The stock was acquired at an average price of $2.93 per share, with a total value of $87,900.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,017,070 shares in the company, valued at approximately $14,700,015.10. The disclosure for this purchase can be found here. 53.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Zacks: Medical Transcription Billing, Corp. (MTBC) Given Average Recommendation of “Strong Buy” by Brokerages” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/08/zacks-medical-transcription-billing-corp-mtbc-given-average-recommendation-of-strong-buy-by-brokerages.html.

About Medical Transcription Billing

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.

Get a free copy of the Zacks research report on Medical Transcription Billing (MTBC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medical Transcription Billing Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related companies with MarketBeat.com's FREE daily email newsletter.